Is exenatide advancing the treatment of Type 2 diabetes?
- 22 December 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (1) , 109-112
- https://doi.org/10.1517/14656566.7.1.109
Abstract
(2006). Is exenatide advancing the treatment of Type 2 diabetes? Expert Opinion on Pharmacotherapy: Vol. 7, No. 1, pp. 109-112. doi: 10.1517/14656566.7.1.109Keywords
This publication has 10 references indexed in Scilit:
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a SulfonylureaDiabetes Care, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 DiabetesDiabetes Care, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Progress with thiazolidinediones in the management of type 2 diabetes mellitusClinical Therapeutics, 2004
- Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 DiabetesDiabetes Care, 2004
- Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 DiabetesDiabetes Care, 2003
- Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2003
- Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group studyThe Lancet, 2002
- Oral Antihyperglycemic Therapy for Type 2 DiabetesJAMA, 2002
- Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.Journal of Biological Chemistry, 1993